Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):405-16. doi: 10.1177/039463201002300203.
Helicobacter pylori is one of the most common infections found in humans. It was first identified in 1982 and by 1989 had been associated with gastric inflammation and ulcers in adults and children. During the 1990's evidence emerged of its etiologic role in stomach cancers in adults. That the infection is common and may have serious consequences, has led to an avalanche of research during the last twenty years. During this time, there have been many studies on children which have sought an effective and safe treatment to eradicate the infection, but as yet, no therapy regimen has been found which is always effective and safe. This article provides information, from a pediatric point of view, on the major developments in the therapeutics and therapy of H. pylori infection. It examines first-line treatment regimens, evaluates the efficacy of the main drugs used in the management of (primary) H. pylori infection in children, assesses the potential for the use of probiotics and sequential therapy, examines therapeutic options after failure of initial treatment, and discusses factors affecting eradication rate, including antibiotic resistance, adherence to therapy, and bacterial factors.
幽门螺杆菌是人类最常见的感染之一。它于 1982 年首次被发现，到 1989 年已被证实与成人和儿童的胃炎症和溃疡有关。在 20 世纪 90 年代，有证据表明它在成人胃癌中起病因作用。由于感染很常见，可能会产生严重后果，因此在过去二十年中进行了大量研究。在此期间，针对儿童进行了许多研究，以寻求一种有效且安全的治疗方法来根除感染，但迄今为止，尚未找到一种始终有效且安全的治疗方案。本文从儿科角度提供了有关幽门螺杆菌感染治疗学和治疗学的主要进展的信息。它首先检查一线治疗方案，评估用于儿童（原发性）幽门螺杆菌感染管理的主要药物的疗效，评估益生菌和序贯疗法的应用潜力，检查初始治疗失败后的治疗选择，并讨论影响根除率的因素，包括抗生素耐药性、治疗依从性和细菌因素。
